Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A.

JAMA Dermatol. 2019 Nov 6. doi: 10.1001/jamadermatol.2019.3336. [Epub ahead of print]

PMID:
31693077
2.

The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature.

Pavel AB, Zhou L, Diaz A, Ungar B, Dan J, He H, Estrada YD, Xu H, Fernandes M, Renert-Yuval Y, Krueger JG, Guttman-Yassky E.

J Am Acad Dermatol. 2019 Oct 24. pii: S0190-9622(19)32961-5. doi: 10.1016/j.jaad.2019.10.039. [Epub ahead of print]

PMID:
31669080
3.

Candidate Predisposition Variants in Kaposi Sarcoma as Detected by Whole-Genome Sequencing.

Rinne SJ, Sipilä LJ, Sulo P, Jouanguy E, Béziat V, Abel L, Casanova JL, Parvaneh N, Balighi K, Guttman-Yassky E, Sarid R, Aaltonen LA, Aavikko M.

Open Forum Infect Dis. 2019 Jul 17;6(10):ofz337. doi: 10.1093/ofid/ofz337. eCollection 2019 Oct.

4.

Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood.

Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T, Rangel S, Kameyama N, Kim HJ, Pavel AB, Estrada Y, Krueger JG, Paller AS, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Oct 15. pii: S0091-6749(19)31319-3. doi: 10.1016/j.jaci.2019.09.031. [Epub ahead of print]

PMID:
31626841
5.

New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines.

Renert-Yuval Y, Guttman-Yassky E.

Ann Allergy Asthma Immunol. 2019 Oct 14. pii: S1081-1206(19)31286-4. doi: 10.1016/j.anai.2019.10.005. [Epub ahead of print] Review.

PMID:
31622669
6.

Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis.

He H, Li R, Choi S, Zhou L, Pavel A, Estrada YD, Krueger JG, Guttman-Yassky E.

Ann Allergy Asthma Immunol. 2019 Oct 14. pii: S1081-1206(19)31294-3. doi: 10.1016/j.anai.2019.10.013. [Epub ahead of print]

PMID:
31622668
7.

Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis.

Guttman-Yassky E, Diaz A, Pavel AB, Fernandes M, Lefferdink R, Erickson T, Canter T, Rangel S, Peng X, Li R, Estrada Y, Xu H, Krueger JG, Paller AS.

JAMA Dermatol. 2019 Oct 9. doi: 10.1001/jamadermatol.2019.2983. [Epub ahead of print]

PMID:
31596431
8.

Atopic Dermatitis Endotypes Based on Allergen Sensitization, Reactivity to Staphylococcus aureus Antigens, and Underlying Systemic Inflammation.

Leonard A, Wang J, Yu L, Liu H, Estrada Y, Greenlees L, McPhee R, Ruzin A, Guttman-Yassky E, Howell MD.

J Allergy Clin Immunol Pract. 2019 Aug 17. pii: S2213-2198(19)30719-6. doi: 10.1016/j.jaip.2019.08.013. [Epub ahead of print]

PMID:
31430591
9.

Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.

Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-Cyr Proulx E, Ports WC, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Nov;144(5):1274-1289. doi: 10.1016/j.jaci.2019.06.047. Epub 2019 Aug 13.

10.

Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis.

Sakurai K, Dainichi T, Garcet S, Tsuchiya S, Yamamoto Y, Kitoh A, Honda T, Nomura T, Egawa G, Otsuka A, Nakajima S, Matsumoto R, Nakano Y, Otsuka M, Iwakura Y, Grinberg-Bleyer Y, Ghosh S, Sugimoto Y, Guttman-Yassky E, Krueger JG, Kabashima K.

J Allergy Clin Immunol. 2019 Oct;144(4):1036-1049. doi: 10.1016/j.jaci.2019.06.019. Epub 2019 Aug 1.

PMID:
31378305
11.

Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis.

Pavel AB, Song T, Kim HJ, Del Duca E, Krueger JG, Dubin C, Peng X, Xu H, Zhang N, Estrada YD, Denis L, Rao N, Gupta S, Zammit DJ, Bissonnette R, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Oct;144(4):1011-1024. doi: 10.1016/j.jaci.2019.07.013. Epub 2019 Jul 26.

PMID:
31356921
12.

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.

Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P, Ardeleanu M, Hultsch T, Guttman-Yassky E, Bissonnette R, Silverberg JI, Krueger J, Menter A, Graham NMH, Pirozzi G, Hamilton JD, Gallo RL.

J Invest Dermatol. 2019 Jun 25. pii: S0022-202X(19)31789-0. doi: 10.1016/j.jid.2019.05.024. [Epub ahead of print]

13.

Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals.

Del Duca E, Pavel AB, Dubin C, Song T, Wallace EB, Peng X, Estrada YD, Xu H, Maari C, Jack C, St-Cyr Proulx E, Krueger JG, Bissonnette R, Guttman-Yassky E.

J Invest Dermatol. 2019 Oct;139(10):2228-2232.e10. doi: 10.1016/j.jid.2019.04.008. Epub 2019 May 3. No abstract available.

PMID:
31059695
14.

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.

Thyssen JP, de Bruin-Weller MS, Paller AS, Leshem YA, Vestergaard C, Deleuran M, Drucker AM, Foelster-Holst R, Traidl-Hoffmann C, Eyerich K, Taieb A, Su JC, Bieber T, Cork MJ, Eichenfield LF, Guttman-Yassky E, Wollenberg A.

J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1224-1231. doi: 10.1111/jdv.15608. Epub 2019 May 6.

15.

The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.

Brunner PM, He H, Pavel AB, Czarnowicki T, Lefferdink R, Erickson T, Canter T, Puar N, Rangel SM, Malik K, Estrada Y, Krueger JG, Guttman-Yassky E, Paller AS.

J Am Acad Dermatol. 2019 Aug;81(2):510-519. doi: 10.1016/j.jaad.2019.04.036. Epub 2019 Apr 19.

PMID:
31009665
16.

The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions.

Guttman-Yassky E, Zhou L, Krueger JG.

J Allergy Clin Immunol. 2019 Aug;144(2):362-374. doi: 10.1016/j.jaci.2019.03.021. Epub 2019 Apr 5.

17.

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E.

Br J Dermatol. 2019 Oct;181(4):733-742. doi: 10.1111/bjd.17932. Epub 2019 May 6.

PMID:
30919407
18.

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement.

Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ, Guttman-Yassky E.

J Eur Acad Dermatol Venereol. 2019 May;33(5):807-815. doi: 10.1111/jdv.15480. Epub 2019 Mar 12.

19.

Conjunctivitis in dupilumab clinical trials.

Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis JD, Mannent L, Hamilton JD, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham NMH, Shumel B, Ardeleanu M, Wollenberg A.

Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.

20.

What's New in Atopic Dermatitis.

Renert-Yuval Y, Guttman-Yassky E.

Dermatol Clin. 2019 Apr;37(2):205-213. doi: 10.1016/j.det.2018.12.007. Epub 2019 Feb 16. Review.

PMID:
30850043
21.

Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.

Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E.

Exp Dermatol. 2019 Jul;28(7):756-768. doi: 10.1111/exd.13911. Epub 2019 Apr 15. Review.

PMID:
30825336
22.

Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice

Lebwohl M, Alexis AF, Beck LA, Block JK, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Boguniewicz M.

J Drugs Dermatol. 2019 Feb 1;18(2):122-129.

PMID:
30794360
23.

GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.

Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H, Peng X, Wen HC, Govas P, Gudi G, Ca V, Fang H, Salhi Y, Back J, Reddy V, Bissonnette R, Maari C, Grossman F, Wolff G.

J Allergy Clin Immunol. 2019 Aug;144(2):482-493.e7. doi: 10.1016/j.jaci.2018.11.053. Epub 2019 Feb 6.

24.

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.

Zhou L, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, Estrada YD, Peng X, Del Duca E, Sanz-Cabanillas J, Ruano J, Xu H, Zhang N, Wen HC, Gonzalez J, Garcet S, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Jul;144(1):144-156. doi: 10.1016/j.jaci.2019.01.015. Epub 2019 Jan 24.

PMID:
30685456
25.

Current and emerging biologic and small molecule therapies for atopic dermatitis.

Li R, Hadi S, Guttman-Yassky E.

Expert Opin Biol Ther. 2019 Apr;19(4):367-380. doi: 10.1080/14712598.2019.1573422. Epub 2019 Feb 7.

PMID:
30672355
26.

Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: Mechanisms and interventions".

Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Busse WW, Chatila TA, Geha RS, Gern JE, Guttman-Yassky E, Irvine AD, Kim BS, Kong HH, Lack G, Nadeau KC, Schwaninger J, Simpson A, Simpson EL, Spergel JM, Togias A, Wahn U, Wood RA, Woodfolk JA, Ziegler SF, Plaut M.

J Allergy Clin Immunol. 2019 Mar;143(3):894-913. doi: 10.1016/j.jaci.2019.01.003. Epub 2019 Jan 9.

PMID:
30639346
27.

Correction to: JAK Inhibitors for Atopic Dermatitis: An Update.

He H, Guttman-Yassky E.

Am J Clin Dermatol. 2019 Apr;20(2):193. doi: 10.1007/s40257-019-00421-1.

PMID:
30632095
28.

Atopic dermatitis endotypes and implications for targeted therapeutics.

Czarnowicki T, He H, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Jan;143(1):1-11. doi: 10.1016/j.jaci.2018.10.032. Review.

PMID:
30612663
29.

Topical agents for the treatment of atopic dermatitis.

Diaz A, Guttman-Yassky E.

Expert Rev Clin Immunol. 2019 Apr;15(4):369-382. doi: 10.1080/1744666X.2019.1564038. Epub 2019 Jan 8.

PMID:
30587053
30.

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases.

Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB, Li R, Estrada Y, Wen HC, Kimmel GW, Kim HJ, Chima M, Lebwohl M, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Jun;143(6):2095-2107. doi: 10.1016/j.jaci.2018.11.031. Epub 2018 Dec 18.

PMID:
30576756
31.

JAK Inhibitors for Atopic Dermatitis: An Update.

He H, Guttman-Yassky E.

Am J Clin Dermatol. 2019 Apr;20(2):181-192. doi: 10.1007/s40257-018-0413-2. Review. Erratum in: Am J Clin Dermatol. 2019 Jan 10;:.

PMID:
30536048
32.

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis.

Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K, Wen HC, Xu H, Estrada YD, Peng X, Chen M, Shah N, Suarez-Farinas M, Pavel AB, Nograles K, Guttman-Yassky E.

J Invest Dermatol. 2019 May;139(5):1063-1072. doi: 10.1016/j.jid.2018.10.043. Epub 2018 Dec 5.

33.

Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients.

Brunner PM, Israel A, Leonard A, Pavel AB, Kim HJ, Zhang N, Czarnowicki T, Patel K, Murphrey M, Ramsey K, Rangel S, Zebda R, Soundararajan V, Zheng X, Estrada YD, Xu H, Krueger JG, Paller AS, Guttman-Yassky E.

Ann Allergy Asthma Immunol. 2019 Mar;122(3):318-330.e3. doi: 10.1016/j.anai.2018.11.025. Epub 2018 Dec 1.

PMID:
30508584
34.

Racial differences in atopic dermatitis.

Brunner PM, Guttman-Yassky E.

Ann Allergy Asthma Immunol. 2019 May;122(5):449-455. doi: 10.1016/j.anai.2018.11.015. Epub 2018 Nov 20. Review.

PMID:
30465859
35.

A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.

Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E.

Arch Dermatol Res. 2019 Jan;311(1):29-36. doi: 10.1007/s00403-018-1876-y. Epub 2018 Nov 11.

PMID:
30417279
36.

Human and computational models of atopic dermatitis: A review and perspectives by an expert panel of the International Eczema Council.

Eyerich K, Brown SJ, Perez White BE, Tanaka RJ, Bissonette R, Dhar S, Bieber T, Hijnen DJ, Guttman-Yassky E, Irvine A, Thyssen JP, Vestergaard C, Werfel T, Wollenberg A, Paller AS, Reynolds NJ.

J Allergy Clin Immunol. 2019 Jan;143(1):36-45. doi: 10.1016/j.jaci.2018.10.033. Epub 2018 Nov 7. Review.

37.

The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition.

Guttman-Yassky E, Hanifin JM, Boguniewicz M, Wollenberg A, Bissonnette R, Purohit V, Kilty I, Tallman AM, Zielinski MA.

Exp Dermatol. 2019 Jan;28(1):3-10. doi: 10.1111/exd.13808. Epub 2018 Dec 12. Review.

PMID:
30332502
38.

Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation.

Sanyal RD, Pavel AB, Glickman J, Chan TC, Zheng X, Zhang N, Cueto I, Peng X, Estrada Y, Fuentes-Duculan J, Alexis AF, Krueger JG, Guttman-Yassky E.

Ann Allergy Asthma Immunol. 2019 Jan;122(1):99-110.e6. doi: 10.1016/j.anai.2018.08.024. Epub 2018 Sep 14.

PMID:
30223113
39.

Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.

Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD.

J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5.

40.

Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata.

Guttman-Yassky E, Nia JK, Hashim PW, Mansouri Y, Alia E, Taliercio M, Desai PN, Lebwohl MG.

Arch Dermatol Res. 2018 Oct;310(8):607-614. doi: 10.1007/s00403-018-1853-5. Epub 2018 Aug 18.

PMID:
30121698
41.

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.

Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17.

PMID:
30121291
42.

Response to "Comment on: 'When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council'".

Simpson EL, Reynolds NJ, Flohr C, Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Irvine AD.

J Am Acad Dermatol. 2018 Aug;79(2):e25-e26. doi: 10.1016/j.jaad.2018.03.048. No abstract available.

PMID:
30012284
43.

An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation.

Song T, Pavel AB, Wen HC, Malik K, Estrada Y, Gonzalez J, Hashim PW, Nia JK, Baum D, Kimmel G, Singer GK, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2018 Nov;142(5):1631-1634.e13. doi: 10.1016/j.jaci.2018.06.029. Epub 2018 Jul 5. No abstract available.

PMID:
29981808
44.

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.

Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A.

JAMA Dermatol. 2018 Aug 1;154(8):903-912. doi: 10.1001/jamadermatol.2018.1572.

45.

Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features.

Chan TC, Sanyal RD, Pavel AB, Glickman J, Zheng X, Xu H, Cho YT, Tsai TF, Wen HC, Peng X, Cueto I, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2018 Sep;142(3):1013-1017. doi: 10.1016/j.jaci.2018.06.016. Epub 2018 Jun 28. No abstract available.

PMID:
29964056
46.

IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis.

Guttman-Yassky E, Krueger JG.

J Invest Dermatol. 2018 Jul;138(7):1467-1469. doi: 10.1016/j.jid.2018.02.037.

47.

Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.

Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R.

J Allergy Clin Immunol. 2019 Jan;143(1):135-141. doi: 10.1016/j.jaci.2018.05.029. Epub 2018 Jun 12.

48.

Successful treatment of juvenile pityriasis rubra pilaris with ustekinumab in a 7-year-old girl.

Bonomo L, Raja A, Tan K, Guttman-Yassky E.

JAAD Case Rep. 2018 Feb 9;4(2):206-210. doi: 10.1016/j.jdcr.2017.09.010. eCollection 2018 Mar. No abstract available.

49.

Monoclonal antibodies for the treatment of atopic dermatitis.

Renert-Yuval Y, Guttman-Yassky E.

Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):356-364. doi: 10.1097/ACI.0000000000000455. Review.

PMID:
29870461
50.

Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.

Brunner PM, Suárez-Fariñas M, He H, Malik K, Wen HC, Gonzalez J, Chan TC, Estrada Y, Zheng X, Khattri S, Dattola A, Krueger JG, Guttman-Yassky E.

Sci Rep. 2018 May 29;8(1):8439. doi: 10.1038/s41598-018-26378-5.

Supplemental Content

Loading ...
Support Center